CoChat

Identification and characterization of RET fusions in advanced colorectal cancer

Open access
Le Rolle, Anne-France, Klempner, Samuel J., Garrett, Christopher R., Seery, Tara, Sanford, Eric M., Balasubramanian, Sohail, Ross, Jeffrey S., Stephens, Philip J., Miller, Vincent A., Ali, Siraj M., Chiu, Vi K. · 2015 · Oncotarget
Cited by 109

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

// Anne-France Le Rolle 1,2,* , Samuel J. Klempner 1,2,* , Christopher R. Garrett 3 , Tara Seery 1,2 , Eric M. Sanford 4 , Sohail Balasubramanian 4 , Jeffrey S. Ross 4,5 , Philip J. Stephens 4 , Vincent A. Miller 4 , Siraj M. Ali 4 and Vi K. Chiu 1,2 1 Division of Hematology/Oncology, Department of Medicine, University of California Irvine, Irvine, CA, USA 2 Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA, USA 3 The Division of Cancer Medicine, Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA 4 Foundation Medicine Inc., Cambridge, MA, USA 5 Albany Medical College, Albany, NY, USA * These authors have contributed equally to this work Correspondence to: Vi K. Chiu, email: // Keywords : RET fusion kinase, RET kinase inhibitor, comprehensive genomic profiling, colorectal cancer Received : April 02, 2015 Accepted : May 12, 2015 Published : May 30, 2015 Abstract There is an unmet clinical need for molecularly directed therapies available for metastatic colorectal cancer. Comprehensive genomic profiling has the potential to identify actionable genomic alterations in colorectal cancer. Through comprehensive genomic profiling we prospectively identified 6 RET fusion kinases, including two novel fusions of CCDC6-RET and NCOA4-RET , in metastatic colorectal cancer (CRC) patients. RET fusion kinases represent a novel class of oncogenic driver in CRC and occurred at a 0.2% frequency without concurrent driver mutations, including KRAS , NRAS , BRAF , PIK3CA or other fusion tyrosine kinases. Multiple RET kinase inhibitors were cytotoxic to RET fusion kinase positive cancer cells and not RET fusion kinase negative CRC cells. The presence of a RET fusion kinase may identify a subset of metastatic CRC patients with a high response rate to RET kinase inhibition. This is the first characterization of RET fusions in CRC patients and highlights the therapeutic significance of prospective comprehensive genomic profiling in advanced CRC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.4325

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 109

Metadata

Authors
Le Rolle, A.-F., Klempner, S. J., Garrett, C. R., Seery, T., Sanford, E. M., Balasubramanian, S., Ross, J. S., Stephens, P. J., Miller, V. A., Ali, S. M., & Chiu, V. K.
Venue
Oncotarget
Published
2015-05-30
Volume
6
Issue
30
Pages
28929-28937
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1875361486
Cited by
109
References
8
FWCI
3.64
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification and characterization of RET fusions in advanced colorectal cancer. https://app.cochat.ai/papers/10.18632/oncotarget.4325
The paper
Le Rolle, A.-F., Klempner, S. J., Garrett, C. R., Seery, T., Sanford, E. M., Balasubramanian, S., Ross, J. S., Stephens, P. J., Miller, V. A., Ali, S. M., & Chiu, V. K. (2015). Identification and characterization of RET fusions in advanced colorectal cancer. Oncotarget. https://doi.org/10.18632/oncotarget.4325

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.